A team of radiologists and radiographers at Oxford University Hospitals and University of Oxford's Department of Oncology has secured a grant to customise a teaching platform to educate frontline NHS staff to diagnose COVID-19 using chest X-rays and CT scans.
The BioEscalator\u2019s inaugural Pitch Battle contest was held digitally at the pizza social on Friday 17 April. Eleven pitches in total were delivered by innovative companies in Oxford's medical research district, covering the broad range of drug discovery, drug development and diagnostics work being undertaken at the BioEscalator.
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.
Dr Nessa Carey will lead the strategic development and implementation of the Entrepreneur in Residence (EiR) programme in Medical Sciences, laying the foundation of a world-class innovation support ecosystem capable of accelerating the translation of world-leading research into innovative therapies, business and commercial products.
Two University of Oxford alumni-led startups, iLoF and Pipra, secured funding in excess of \u20ac4M from the European Institute of Technology for Health (EIT Health).
Up to 30,000 lives could be saved over the next decade thanks to a proposed pioneering government collaboration with pharmaceutical company Novartis to tackle heart disease \u2013 a leading cause of death in the UK.
On 1 October 2019, the University of Oxford and the University of British Columbia (UBC) signed a Memorandum of Understanding, committing to work together to develop a new generation of clinical research leaders who will transform the translation of novel therapies from laboratory to clinic.
The University of Oxford and its partner organisations have been awarded funding that will support the training of over 175 bioscience graduate students as part of \u00a3170 million investment in bioscience by the BBSRC (Biotechnology and Biosciences Research Council, part of UK Research and Innovation).
Researchers at the University of Oxford have discovered that male fruit flies adjust their seminal fluid depending on the levels of competition from other males.
LAB10x aims to accelerate the commercialisation of the next generation of digital therapeutics and data-driven drug discovery from clinical artificial intelligence research and digital health innovations at Oxford University.
Oxford Brain Diagnostics, a spinout from Oxford University, has been launched to deliver a new method for diagnosing Alzheimer\u2019s Disease from MRI scans.
The new 7-year research collaboration with Janssen Research & Development, LLC (Janssen) will study patients at higher risk of developing certain types of blood cancers that arise from the immune system, such as chronic lymphocytic leukaemia and multiple myeloma, to identify markers that could be used to predict who will go on to develop symptomatic disease.
A new strategic partnership between Fiocruz and The Global Health Network will amplify the impact of Fiocruz\u2019s health research and capacity development initiatives by promoting research capacity building across Portuguese-speaking countries, and enabling research findings from the Zika outbreak to benefit public health worldwide.
Six new Oxford-Celgene Fellowships will support postdoctoral researchers and clinicians across six departments within the Medical Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development. The new Fellowships represent an additional investment of \u00a33M into the University.
Medical Sciences Division is delighted to welcome Dr Anjan Thakurta to Oxford, having now taken up his position of Visiting Professor of Cancer, Biology and Translational Science within the Radcliffe Department of Medicine.
A new clinical trial is testing a virtual reality (VR) based psychological therapy for people with severe mental health difficulties. gameChange is the largest ever clinical trial of virtual reality for a mental health disorder. Automated delivery of therapy using VR has potential to transform NHS provision of psychological therapy.
The MSD Business Development & Partnering team have been shortlisted in the PraxisAuril and UK Research and Innovation (UKRI) 2019 Knowledge Exchange Awards, in the category of 'Knowledge Exchange Team of the Year'.
![\"Digital](\"https://www.medsci.ox.ac.uk/news/new-partnership-aims-to-significantly-reduce-the-incidence-of-hip-and-vertebral-fractures/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n